British pharmaceutical giant GlaxoSmithKline (GSK) has entered India’s oncology space with the launch of two advanced therapies, Jemperli (dostarlimab) and Zejula (niraparib), in a move that goes ...
NEW DELHI: GlaxoSmithKline (GSK) on Monday announced its foray into the Indian oncology market with the launch of two precision therapies — Jemperli (dostarlimab) and Zejula (niraparib) — aimed at ...
Aug 3 (Reuters) - Vaccine maker GlaxoSmithKline Pharmaceuticals reported a 15.7% rise in first-quarter profit on Monday, aided by stable demand across its vaccine and drug portfolio, including ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
GSK’s India-listed pharma arm is flying under the radar, even as the global parent reshapes its vaccine and specialty-drug pipeline. Here is why this secondary play could matter more to US investors ...
GSK India plans to double its revenue to around Rs 8,000 crore by FY30, MD Bhushan Akshikar said. The company aims to drive growth through its pharmaceutical and consumer health portfolio, ...
GSK Pharma maintains a significant presence in India’s prescription drug market, with a portfolio spanning vaccines, respiratory treatments and other specialty medicines. For investors, the company’s ...
MUMBAI, Dec 16 (Reuters) - GlaxoSmithKline Plc (GSK) has decided to spend roughly $1 billion to raise its stake in its Indian pharmaceutical unit, betting on rising demand in emerging markets as sales ...
The Indian subsidiaries of two European drugmakers, GlaxoSmithKline (GSK) and Sanofi, have been fined for allegedly plotting to charge higher prices in a government tender for a meningitis vaccine, ...
Citing an anticompetitive agreement that was “clearly made out,” India’s Competition Commission took issue with GlaxoSmithKline and Sanofi’s operations in the country this week and fined the ...
GSK increases stake in Indian Pharmaceuticals subsidiary to 75 per cent after Open Offer David Redfern, Chief Strategy Officer, GSK said: "We are very pleased with the outcome of this transaction, ...
Nov 3 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported slightly higher second-quarter profit on Thursday, led by steady demand for its specialty medicine portfolio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results